Methylation of imprinting gene as marker for early diagnosis of cardiovascular and cerebrovascular diseases
A cardiovascular and cerebrovascular disease and methylation technology, applied in the medical field to improve the effect of early diagnosis and treatment
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0135] Example 1. Primer Design for Detection of SLC22A18 Gene Methylation Sites
[0136] After extensive sequence and functional analysis, four fragments (SLC22A18_A fragment, SLC22A18_B fragment, SLC22A18_C fragment and SLC22A18_D fragment) in the imprinted gene SLC22A18 (Solute CarrierFamily22, member18, SLC22A18) were selected for correlation between methylation level and cardiovascular and cerebrovascular diseases analyze.
[0137] The SLC22A18_A fragment (SEQ ID No.1) is located in hg19 reference genome chr11:2920020-2920844, positive sense strand.
[0138] The SLC22A18_B fragment (SEQ ID No.2) is located at hg19 reference genome chr11:2921564-2922490, antisense strand.
[0139] The SLC22A18_C fragment (SEQ ID No.3) is located at hg19 reference genome chr11:2924390-2925287, positive sense strand.
[0140] The SLC22A18_D fragment (SEQ ID No.4) is located in hg19 reference genome chr11:2925321-2926242, positive sense strand.
[0141] The CpG site information in the SLC2...
Embodiment 2
[0159] Example 2, SLC22A18 gene methylation detection and result analysis
[0160] 1. Research samples
[0161] The research sample adopts the epidemiological cluster sampling method, and conducts a follow-up survey on the community population over 18 years old in a certain city for more than 2 years. This study was reviewed by the Ethics Committee, and all subjects signed the informed consent. Cardiovascular and cerebrovascular diseases and cancer incidence information are recorded every year through local hospitals, CDC chronic disease management system, community health service centers and workstation chronic disease routine registration items, and social security center reimbursement data. The start time of the cohort is the baseline survey date, and the outcome variable is cardiovascular and cerebrovascular diseases. For the lost follow-up subjects, the follow-up time is uniformly calculated as half of the end time of the follow-up. As of the follow-up date in July 2018...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


